In Vitro Activities of DU-1102, a New Trioxaquine Derivative, against Plasmodium falciparum Isolates

ABSTRACT The antimalarial trioxaquine derivative DU-1102, synthesized by covalent linkage between aminoquinoline and trioxane moieties, was highly active against Cameroonian isolates (mean 50% inhibitory concentration of 43 nmol/liter) of Plasmodium falciparum. There was no correlation between the responses to DU-1102 and chloroquine and only a low correlation between the responses to DU-1102 and pyrimethamine, suggesting an independent mode of action of the trioxaquine against the parasites.

[1]  Anne Robert,et al.  Alkylation of heme by artemisinin, an antimalarial drug , 2001 .

[2]  B. Meunier,et al.  Preparation and Antimalarial Activities of “Trioxaquines”, New Modular Molecules with a Trioxane Skeleton Linked to a 4‐Aminoquinoline , 2000, Chembiochem : a European journal of chemical biology.

[3]  P. Ringwald,et al.  Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998. , 1999, The American journal of tropical medicine and hygiene.

[4]  T. Egan,et al.  THE ROLE OF HAEM IN THE ACTIVITY OF CHLOROQUINE AND RELATED ANTIMALARIAL DRUGS , 1999 .

[5]  M. Avery,et al.  Current progress in the chemistry, medicinal chemistry and drug design of artemisinin based antimalarials. , 1999, Current pharmaceutical design.

[6]  P. Ringwald,et al.  In Vitro Activity of Lumefantrine (Benflumetol) against Clinical Isolates of Plasmodium falciparum in Yaoundé, Cameroon , 1998, Antimicrobial Agents and Chemotherapy.

[7]  B. Meunier,et al.  Alkylating Properties of Antimalarial Artemisinin Derivatives and Synthetic Trioxanes when Activated by a Reduced Heme Model , 1998 .

[8]  J. Cumming,et al.  Design, synthesis, derivatization, and structure-activity relationships of simplified, tricyclic, 1,2,4-trioxane alcohol analogues of the antimalarial artemisinin. , 1998, Journal of medicinal chemistry.

[9]  Anne Robert,et al.  Is alkylation the main mechanism of action of the antimalarial drug artemisinin , 1998 .

[10]  B. Meunier,et al.  Characterization of the First Covalent Adduct between Artemisinin and a Heme Model , 1997 .

[11]  J. Cumming,et al.  Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. , 1997, Advances in pharmacology.

[12]  P. Olliaro,et al.  Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. , 1996, Parasitology today.

[13]  S. Meshnick,et al.  Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. , 1996, Microbiological reviews.

[14]  P. Ringwald,et al.  Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa , 1996, The Lancet.

[15]  W. Milhous,et al.  Structure-activity relationships of the antimalarial agent artemisinin. 1. Synthesis and comparative molecular field analysis of C-9 analogs of artemisinin and 10-deoxoartemisinin. , 1993, Journal of medicinal chemistry.

[16]  W. Peters,et al.  The prevention of antimalarial drug resistance. , 1990, Pharmacology & therapeutics.

[17]  B. Nahlen,et al.  Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine. , 1989, Bulletin of the World Health Organization.

[18]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.